ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Triple Negative Breast Cancer

Melanoma trials near Taipei City, TWN:

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Active, not recruiting
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Taipei, Taiwan and 110 other locations

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Pembrolizumab

Phase 2

Mural Oncology

Taipei, Taiwan and 43 other locations

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling
Melanoma
Drug: ABP 206
Drug: Nivolumab

Phase 3

Amgen
Amgen

Taipei, Taiwan and 166 other locations

is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...

Active, not recruiting
Melanoma
Biological: Pembrolizumab
Biological: V940

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 165 other locations

in combination with Yervoy-EU (induction phase only), in participants with advanced (unresectable Stage III or metastatic Stage IV) melanoma....

Enrolling
Melanoma
Drug: JPB898 (Induction and Maintenance)
Drug: Opdivo-EU (Maintenance)

Phase 3

Sandoz
Sandoz

Taoyuan City, Taiwan and 32 other locations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

Phase 1

Pierre Fabre
Pierre Fabre

Taipei, Taiwan and 30 other locations

and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with N...

Active, not recruiting
Melanoma
Nasopharyngeal Carcinoma
Drug: DKY709
Drug: PDR001

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination w...

Active, not recruiting
Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)

Phase 1

Novartis
Novartis

Taipei, Taiwan and 17 other locations

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Begins enrollment in 1 month
Solid Tumors
Drug: DB-1311/BNT324
Drug: DB-1305/BNT325

Phase 2

DualityBio

Taipei City, Taipei, Taiwan and 14 other locations

solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and nec...

Enrolling
Melanoma
Endometrial Cancer
Drug: HER3-DXd

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 59 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems